Starpharma announces DEP cabazitaxel Phase 1/2 Trial
Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals.
Starpharma to commence DEP® cabazitaxel phase 1/2 trial
Starpharma today announced that it has received regulatory and ethics approvals to commence its phase 1/2 clinical trial for DEP® cabazitaxel. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® cabazitaxel, to define a recommended phase 2 dose (RP2D), and then to determine anti-tumour efficacy of the product in select tumour types.
Appendix 4C - Quarterly Cashflow Report
Starpharma (ASX: SPL, OTCQX: SPHRY) released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2017.
AstraZeneca plans to make better use of Australia’s innovation
|
The Australian highlighted Starpharma’s partnership with global pharmaceutical company AstraZeneca, noting the application of Starpharma’s DEP® technology platform helps make cancer drugs more effective, more patient-friendly and less toxic. |